Journal: Cell

Article Title: B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV

doi: 10.1016/j.cell.2021.04.032

Figure Lengend Snippet:

Article Snippet: HRP Conjugated Goat anti-Human Lambda Light Chain Antibody , Bio-Rad , Cat#STAR129P; RRID: AB_1102721.

Techniques: Virus, Recombinant, Staining, Plasmid Preparation, Expressing, Modification, Luciferase, Cell Culture, Lysis, Reporter Gene Assay, Enzyme-linked Immunosorbent Assay, Electron Microscopy, Cloning, Software, Chromatography, Spectrophotometry

Journal: Blood

Article Title: Myeloma cell–derived Runx2 promotes myeloma progression in bone

doi: 10.1182/blood-2014-12-613968

Figure Lengend Snippet: Runx2 knockdown inhibits MM progression in vivo. (A) Expression of Runx2 in 2 Runx2 k/d 5TGM1 cell lines (Runx2 shRNA #90– and Runx2 shRNA #91–transfected 5TGM1 cells) was probed by western blot. Both Runx2 shRNA #90 and #91 decreased the expression of Runx2 compared with NT control. (B) Serum IgG2bκ was measured by ELISA 6 weeks after IV injection of NT control or Runx2 k/d 5TGM1 cells. Error bars represent mean ± SEM (n = 10 animals per group). Significant differences between groups are indicated by P value. (C) H&E-stained bone sections from mice injected IV with either NT control or Runx2 k/d 5TGM1 cells. Tumors were present in mice injected with NT cells, but not in the mice injected with Runx2 k/d cells (original magnification, ×100). Inset, Abundant myeloma cells in NT-bearing mice compared with Runx2 k/d 5TGM1 cell-injected mice. (D) Survival was significantly increased in mice injected IV with 5TGM1 Runx2 k/d cells (clone #90 and #91) compared with those injected with NT 5TGM1 cells. (E) Six weeks after intratibial injection of Runx2 k/d or NT 5TGM1 cells, levels of serum IgG2bκ were measured by ELISA. Error bars represent mean ± SEM (n = 10 animals per group). Significant differences between groups are indicated by P value. (F) Western blot shows reduction of Runx2 expression in MM.1R cells transduced with Runx2 shRNA compared with wild-type (WT) or NT control cells. (G) Six weeks after s.c. injection of NT or Runx2 k/d human MM.1R cells, serum human Ig λ light chain was measured by ELISA. Error bars represent mean ± SEM (n = 10 animals per group). Significant differences between groups are indicated by P value.

Article Snippet: The levels of human Ig λ light chain or mouse IgG2bκ in mouse sera were measured using human Ig λ or mouse IgG2bκ ELISA kits (Bethyl Laboratories Inc), respectively.

Techniques: Knockdown, In Vivo, Expressing, shRNA, Transfection, Western Blot, Control, Enzyme-linked Immunosorbent Assay, IV Injection, Staining, Injection, Transduction

Journal: Discover Oncology

Article Title: IGLC1 is an independent prognostic marker and potent therapeutic target in osteosarcoma

doi: 10.1007/s12672-025-02653-6

Figure Lengend Snippet: IGLC1 expression in osteosarcoma and non-neoplastic bone specimens. A Representative immunohistochemical staining of IGLC1 in osteosarcoma tissues and non-neoplastic bone specimens. Scale bars: 100 μm (top) and 50 μm (bottom). B Immunohistochemical scores of IGLC1 expression were significantly higher in osteosarcoma tissues compared to non-neoplastic bone specimens; **** P < 0.001

Article Snippet: The membranes were then incubated with primary antibodies against IGLC1 (Cat. No. #20,758–1-AP, 1:500 dilution, Proteintech Group, Wuhan, China) and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Cat. No. #380,626; 1:5000; Zenbio, Chengdu, China) overnight at 4 °C and HRP-conjugated secondary antibodies (Cat. No. 550064; 1:10,000; Zenbio, Chengdu, China) for 1 h. The membranes were washed 3 times with 1 × TBST (Cat. No. BL315B, Biosharp, Hefei, China) and immersed in enhanced chemiluminescence solution (Cat. No. BL520A, Biosharp, Hefei, China).

Techniques: Expressing, Immunohistochemical staining, Staining

Journal: Discover Oncology

Article Title: IGLC1 is an independent prognostic marker and potent therapeutic target in osteosarcoma

doi: 10.1007/s12672-025-02653-6

Figure Lengend Snippet: Kaplan–Meier survival analysis of overall survival in osteosarcoma patients. A Patients with high IGLC1 expression had significantly poorer overall survival compared to those with low expression (HR = 3.028, 95% CI = 1.687–5.437, P < 0.001). B Patients with high LDH levels exhibited significantly poorer overall survival compared to those with normal LDH levels (HR = 2.793, 95% CI = 1.630–4.789, P < 0.001)

Article Snippet: The membranes were then incubated with primary antibodies against IGLC1 (Cat. No. #20,758–1-AP, 1:500 dilution, Proteintech Group, Wuhan, China) and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Cat. No. #380,626; 1:5000; Zenbio, Chengdu, China) overnight at 4 °C and HRP-conjugated secondary antibodies (Cat. No. 550064; 1:10,000; Zenbio, Chengdu, China) for 1 h. The membranes were washed 3 times with 1 × TBST (Cat. No. BL315B, Biosharp, Hefei, China) and immersed in enhanced chemiluminescence solution (Cat. No. BL520A, Biosharp, Hefei, China).

Techniques: Expressing

Journal: Discover Oncology

Article Title: IGLC1 is an independent prognostic marker and potent therapeutic target in osteosarcoma

doi: 10.1007/s12672-025-02653-6

Figure Lengend Snippet: Functional effects of IGLC1 knockdown in osteosarcoma cells. A IGLC1 knockdown efficiency was validated by real-time PCR and western blot assays. B CCK-8 assay showed a significant reduction in cell proliferation following IGLC1 knockdown. C Colony formation assay revealed that IGLC1 knockdown significantly impaired the clonogenic ability of osteosarcoma cells. D , E Transwell migration and wound healing assays demonstrated that IGLC1 knockdown markedly reduced cell migration ability. F Transwell invasion assay showed that IGLC1 knockdown significantly decreased the invasive potential of osteosarcoma cells. Note : *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Usually the blots were cut prior to hybridisation with antibodies

Article Snippet: The membranes were then incubated with primary antibodies against IGLC1 (Cat. No. #20,758–1-AP, 1:500 dilution, Proteintech Group, Wuhan, China) and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Cat. No. #380,626; 1:5000; Zenbio, Chengdu, China) overnight at 4 °C and HRP-conjugated secondary antibodies (Cat. No. 550064; 1:10,000; Zenbio, Chengdu, China) for 1 h. The membranes were washed 3 times with 1 × TBST (Cat. No. BL315B, Biosharp, Hefei, China) and immersed in enhanced chemiluminescence solution (Cat. No. BL520A, Biosharp, Hefei, China).

Techniques: Functional Assay, Knockdown, Real-time Polymerase Chain Reaction, Western Blot, CCK-8 Assay, Colony Assay, Migration, Transwell Invasion Assay, Hybridization